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Abstract 
An adequately sampled tumor histology that is evaluated by an experienced neuropa-
thologist is the current international standard for the diagnosis of high-grade gliomas. We 
present the case of a 30-year-old female for whom clinical and radiological information 
dramatically changed the histological diagnosis. We suggest a new algorithm including these 
parameters to refine the accuracy of histological diagnosis both for standard treatment and 
centrally reviewed clinical trials. © 2013 S. Karger AG, Basel 
Introduction 
An adequately sampled tumor histology that is evaluated by an experienced neuropa-
thologist is the current international standard for the diagnosis of high-grade gliomas and 
sets the stage for adjuvant treatment in the field of neurooncology [1]. However, standard 
histology, including H&E staining, and standard immunohistochemistry markers, such as 
GFAP, neglect the recent development of molecular markers as well as clinical and imaging 
information [2]. 
Case Report 
A 30-year-old female presented at our clinic with moderate aphasia of a few weeks’ 
duration 14 days after she had been diagnosed with anaplastic astrocytoma based on an 
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open biopsy of her left temporal lobe at an external hospital. She had a 2-year history of 
complex focal epileptic seizures prior to diagnosis. Due to a substantial mass effect of the 
remaining tumor, an interdisciplinary consensus was followed, and part of the remaining 
tumor was resected with a substantial relief of the mass effect (fig. 1a) and almost complete 
recovery of aphasia, with a Karnofsky performance score of 90%. The diagnosis of anaplastic 
astrocytoma was confirmed by the local neuropathologist, taking into consideration that 
some of the reactive and regressive changes (fig. 1b–f) were attributable to the preceding 
biopsy. The presence of a mutation of isocitrate dehydrogenase (IDH1), a marker of grade II 
and III gliomas and secondary glioblastomas, substantiated the diagnosis [3]. After central 
review of the histology by 2 reference neuropathologists, randomization into an internation-
al clinical trial for anaplastic gliomas was rejected due to the fact that necrosis in the 
histological samples obtained during the second surgery qualified, in the view of the 
reference neuropathologists, as glioblastoma. At that point, considering the size of the 
residual tumor mass and in view of the clinical history and an MRI suggestive of a rather 
aggressive high-grade glioma, we decided to start the patient on radiochemotherapy with 
temozolomide according to the Stupp protocol [4]. 
Conclusions 
We believe that this case illustrates some of the limitations of the current process of how 
diagnoses for patients with high-grade gliomas are made. First, a tumor biopsy, open or 
stereotactic, selects a small portion of the tumor which may not necessarily represent the 
total tumor mass. Second, molecular information, such as IDH1 mutation, can add substantial 
information to the kind and dignity of the tumor. Third, information from MRI and the 
dynamics of the clinical course may substantially differ from the histological information 
from the tumor biopsies and may enhance a comprehensive evaluation of the individual 
course. And fourth, local and particularly central review neuropathologists are often not 
adequately supported with clinical and imaging information to make a conclusive diagnosis. 
Since a change in the diagnosis implicates a substantial change in the treatment for the 
affected patient, we therefore mandate gross total resections, whenever applicable, to obtain 
a maximal amount of tumor material, along with the integration of imaging and clinical 
information in the material submitted to local and central neuropathology [5]. We think that 
the minimal time delay incurred before treatment by establishing such an algorithm would 
be negligible; the algorithm would favor diagnostic accuracy and advance both standard 
treatment and the homogeneity of study populations within centrally reviewed clinical trials. 
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Fig. 1. a Postoperative MRI scan performed within 24 h after the second resection. FLAIR, T2 and T1 
sequences with and without contrast-enhancing gadolinium. The single asterisk (*) marks the initial 
external hospital biopsy site, whereas the double asterisk (**) marks the area of the gross resection at our 
institution. There is pronounced gadolinium enhancement in the dorsal parts of the tumor, including 
necrotic areas and signs of hypervascularization. b–f Histology of the gross resection. b Most parts of the 
tumor appear as anaplastic astrocytoma, lacking necrosis or vascular proliferation. In some parts, 
histological changes were detected (c–f) that could most likely be attributed to the prior stereotactic 
biopsy: focal areas of surrounding necrotic non-neoplastic brain tissue with low cellularity (c); necrotic 
tumor areas intermixed with granulocytic infiltrates (d); hemosiderin deposits as a sign of a previous 
hemorrhage (arrows, e), and reactive inflammation surrounding blood vessels (f). 
 
D
ow
nl
oa
de
d 
by
: 
Un
ive
rs
itä
ts
bi
bl
io
th
ek
, R
eg
en
sb
ur
g
13
2.
19
9.
14
5.
54
 - 
12
/6
/2
01
3 
10
:5
6:
03
 A
M
